<!DOCTYPE html>
<html>
<head>
    <title>PressReader - The Straits Times: 2020-07-28 - Moderna en&#xAD;ters late-stage vac&#xAD;cine trial, with back&#xAD;ing from US govt</title>
    <meta name="description" content="">
    <meta content="magazines, newspapers, digital news, reading, news, breaking news, newspaper online" name="keywords">
    <meta name="Robots" content="NOARCHIVE,NOODP">
    <meta charset="UTF-8">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    
    <link rel="canonical" href="/singapore/the-straits-times/20200728/281775631484793" />


    <style>
        li {
            margin: 1em 0;
        }
        img {
            max-width: 100%;
        }
        p, h1, h2, h3 {
            max-width: 100%;
        }
    </style>
</head>
<body>
    <div>
        

<article>
    <h1>Moderna en&#xAD;ters late-stage vac&#xAD;cine trial, with back&#xAD;ing from US govt</h1>
    <h2></h2>
    <section>
        <a href="/singapore/the-straits-times/textview" title="The Straits Times">The Straits Times</a>
        - <a href="/singapore/the-straits-times/20200728/textview" title="The Straits Times - 2020-07-28"><time>2020-07-28</time></a>
        - <span>WORLD</span>
        - <span role="byline"></span>
    </section>

    <p>MASS­A­CHU­SETTS • Moderna said yes­ter­day it has started a United States govern­ment-backed lat­estage trial for its Covid-19 vac­cine can­di­date, the first to be im­ple­mented un­der the Trump ad­min­is­tra­tion’s Op­er­a­tion Warp Speed anti-coro­n­avirus pro­gramme.</p>
    <p>News of the study, which will test the re­sponse to the vac­cine in 30,000 adults who do not have the res­pi­ra­tory ill­ness, pushed shares in Cam­bridge, Mas­sachusetts­based Moderna up more than 8 per cent be­fore the bell.</p>
    <p>The fed­eral govern­ment is sup­port­ing Moderna’s vac­cine project with nearly US$1 bil­lion (S$1.38 bil­lion) and has cho­sen it as one of the first to en­ter large-scale hu­man tri­als.</p>
    <p>The US govern­ment now plans to spend up to US$472 mil­lion on top of the pre­vi­ously an­nounced US$483 mil­lion, Moderna an­nounced on Sun­day.</p>
    <p>With lab­o­ra­to­ries around the world in a fu­ri­ous race to develop the first ef­fec­tive vac­cine, Moderna seems to hold the lead as it en­ters a fi­nal round of clin­i­cal tri­als – a de­ci­sive step in de­ter­min­ing whether a vac­cine is both ef­fec­tive and safe.</p>
    <p>Chi­nese biotech firm Si­no­vac said on July 6 that it, too, would be­gin a Phase III clin­i­cal trial this month, in col­lab­o­ra­tion with Brazil’s Bu­tan­tan bi­o­logic re­search cen­tre.</p>
    <p>Also re­port­ing en­cour­ag­ing re­sults is a Bri­tish project de­vel­oped by Ox­ford Univer­sity in part­ner­ship with the multi­na­tional As­traZeneca lab­o­ra­tory.</p>
    <p>In all, nearly 200 can­di­date vac­cines are in de­vel­op­ment, in­clud­ing 23 now in the clin­i­cal phase and be­ing tested on hu­mans.</p>
    <p>“Hav­ing a safe and ef­fec­tive vac­cine dis­trib­uted by the end of 2020 is a stretch goal, but it’s the right goal for the Amer­i­can peo­ple,” US Na­tional In­sti­tutes of Health direc­tor Fran­cis Collins said.</p>
    <p>Moderna said it re­mains on track to de­liver about 500 mil­lion doses a year, and pos­si­bly up to one bil­lion doses a year, start­ing next year.</p>
    <p>The trial is de­signed to eval­u­ate the safety of Moderna’s mRNA-1273 and de­ter­mine if it can pre­vent symp­to­matic Covid-19 af­ter two doses.</p>
    <p>The study also seeks to an­swer if the vac­cine can pre­vent death caused by Covid-19 and if just one dose can pre­vent symp­to­matic Covid-19, among other ob­jec­tives.</p>
    <p>Last Wed­nes­day, the Amer­i­canGer­man BioNTech/Pfizer phar­ma­ceu­ti­cal al­liance an­nounced that the US govern­ment had com­mit­ted US$1.95 bil­lion to pro­cure 100 mil­lion doses of its even­tual vac­cine.</p>
    <p>Emer­gent BioSo­lu­tions said yes­ter­day it signed a US$174 mil­lion agree­ment with As­traZeneca to develop and man­u­fac­ture the Bri­tish drug­maker’s vac­cine can­di­date.</p>
    <p>Last month, As­traZeneca picked Emer­gent to help pro­duce the 300 mil­lion doses of its po­ten­tial Covid-19 vac­cine pledged to the US.</p>


</article>

<section>
    <h3><a href="/catalog/language/english">Newspapers in English</a></h3>
    <h3><a href="/catalog/country/singapore">Newspapers from Singapore</a></h3>
</section>

    </div>
    
    <p><a href="http://www.pressreader.com">© PressReader. All rights reserved.</a></p>

        <script>
            (function (i, s, o, g, r, a, m) {
                i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () {
                    (i[r].q = i[r].q || []).push(arguments);
                }, i[r].l = 1 * new Date();
                a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g;
                m.parentNode.insertBefore(a, m);
            })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
        </script>
        <script>
            ga('create', 'UA-44408245-1');
            ga('send', 'pageView');
        </script>
</body>
</html>
